Oyster Point Pharma, Inc.

2021 Q4 Form 10-Q Financial Statement

#000172072521000095 Filed on November 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q4

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $193.4M $184.2M $192.6M
YoY Change 0.4% -14.06% 38.46%
Cash & Equivalents $193.4M $184.2M $192.6M
Short-Term Investments
Other Short-Term Assets $9.136M $3.020M $3.800M
YoY Change 140.42% 235.56% 26.67%
Inventory $6.086M $0.00
Prepaid Expenses
Receivables $6.656M $0.00
Other Receivables $0.00
Total Short-Term Assets $215.3M $189.7M $196.4M
YoY Change 9.62% -11.85% 38.11%
LONG-TERM ASSETS
Property, Plant & Equipment $2.497M $1.976M $804.0K
YoY Change 210.57% 324.03% 344.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $886.0K
YoY Change
Other Assets $1.082M $2.635M $0.00
YoY Change 2535.0%
Total Long-Term Assets $7.367M $5.323M $1.543M
YoY Change 377.45% 308.21% 49.95%
TOTAL ASSETS
Total Short-Term Assets $215.3M $189.7M $196.4M
Total Long-Term Assets $7.367M $5.323M $1.543M
Total Assets $222.6M $195.0M $197.9M
YoY Change 12.48% -9.92% 38.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.496M $3.506M $2.279M
YoY Change 185.04% 53.03% 349.51%
Accrued Expenses $21.51M $11.17M $8.285M
YoY Change 159.64% 65.61% 80.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $16.00K $17.00K $0.00
YoY Change
Total Short-Term Liabilities $28.80M $15.16M $10.98M
YoY Change 162.27% 60.48% 103.41%
LONG-TERM LIABILITIES
Long-Term Debt $89.82M $41.93M $0.00
YoY Change
Other Long-Term Liabilities $2.345M $238.0K $0.00
YoY Change -40.5% -100.0%
Total Long-Term Liabilities $2.345M $42.34M $269.0K
YoY Change 771.75% 10484.0% -46.2%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.80M $15.16M $10.98M
Total Long-Term Liabilities $2.345M $42.34M $269.0K
Total Liabilities $123.1M $57.50M $11.25M
YoY Change 993.95% 485.33% 90.34%
SHAREHOLDERS EQUITY
Retained Earnings -$255.4M -$213.3M -$154.8M
YoY Change 65.05% 60.98% 83.72%
Common Stock $27.00K $26.00K $26.00K
YoY Change 3.85% 0.0% 23.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $99.54M $137.5M $186.7M
YoY Change
Total Liabilities & Shareholders Equity $222.6M $195.0M $197.9M
YoY Change 12.48% -9.92% 38.2%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q4

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001720725
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39112
dei Entity Registrant Name
EntityRegistrantName
OYSTER POINT PHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-1030955
dei Entity Address Address Line1
EntityAddressAddressLine1
202 Carnegie Center, Suite 109
dei Entity Address City Or Town
EntityAddressCityOrTown
Princeton
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08540
dei City Area Code
CityAreaCode
609
dei Local Phone Number
LocalPhoneNumber
382-9032
dei Security12b Title
Security12bTitle
Common stock, par value $0.001
dei Trading Symbol
TradingSymbol
OYST
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26163861 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
184166000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192585000 USD
CY2021Q3 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
2500000 USD
CY2020Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
0 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3020000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3782000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
189686000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
196367000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1976000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
804000 USD
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
61000 USD
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
61000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2635000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2021Q3 oyst Lease Right Of Use Asset
LeaseRightOfUseAsset
651000 USD
CY2020Q4 oyst Lease Right Of Use Asset
LeaseRightOfUseAsset
678000 USD
CY2021Q3 us-gaap Assets
Assets
195009000 USD
CY2020Q4 us-gaap Assets
Assets
197910000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3506000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2279000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11174000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8285000 USD
CY2021Q3 oyst Lease Liability Current
LeaseLiabilityCurrent
481000 USD
CY2020Q4 oyst Lease Liability Current
LeaseLiabilityCurrent
418000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
15161000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10982000 USD
CY2021Q3 oyst Lease Liability Noncurrent
LeaseLiabilityNoncurrent
179000 USD
CY2020Q4 oyst Lease Liability Noncurrent
LeaseLiabilityNoncurrent
269000 USD
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
41919000 USD
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
0 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
238000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2021Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
42336000 USD
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
269000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
57497000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
11251000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26094253 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26094253 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25890490 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25890490 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
26000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
26000 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
350832000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
341384000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-213346000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-154751000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
137512000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
186659000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
195009000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
197910000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17943000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17943000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17943000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17943000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6214000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8210000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18772000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28104000 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28497000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8112000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
56885000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20641000 USD
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
34711000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
16322000 USD
us-gaap Operating Expenses
OperatingExpenses
75657000 USD
us-gaap Operating Expenses
OperatingExpenses
48745000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16768000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16322000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-57714000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-48745000 USD
CY2021Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
222000 USD
CY2020Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
17000 USD
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
243000 USD
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
457000 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
1124000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
1124000 USD
us-gaap Interest Expense
InterestExpense
0 USD
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-902000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
17000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-881000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
457000 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17670000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16305000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58595000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48288000 USD
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.05
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26037975 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26037975 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25797282 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25797282 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25984412 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25984412 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23544035 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23544035 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
186659000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18909000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
218000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2680000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
170648000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-22016000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
104000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3048000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
151784000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-17670000 USD
CY2021Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
87816 shares
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
283000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3115000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
137512000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
137298000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-16519000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1180000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
121963000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-15464000 USD
CY2020Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
8125000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
112625000 USD
CY2020Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
60425 shares
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
82000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1609000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1609000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
220815000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-16305000 USD
CY2020Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
87755 shares
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
173000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1990000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
206673000 USD
us-gaap Net Income Loss
NetIncomeLoss
-58595000 USD
us-gaap Net Income Loss
NetIncomeLoss
-48288000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
8843000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
4779000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
91000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
57000 USD
oyst Amortization And Accretion Of Loan Term Debt Related Costs
AmortizationAndAccretionOfLoanTermDebtRelatedCosts
508000 USD
oyst Amortization And Accretion Of Loan Term Debt Related Costs
AmortizationAndAccretionOfLoanTermDebtRelatedCosts
0 USD
oyst Increase Decrease In Operating Right Of Use Assets
IncreaseDecreaseInOperatingRightOfUseAssets
-371000 USD
oyst Increase Decrease In Operating Right Of Use Assets
IncreaseDecreaseInOperatingRightOfUseAssets
-285000 USD
oyst Revenue From Related Party Non Cash Consideration License Revenue
RevenueFromRelatedPartyNonCashConsiderationLicenseRevenue
443000 USD
oyst Revenue From Related Party Non Cash Consideration License Revenue
RevenueFromRelatedPartyNonCashConsiderationLicenseRevenue
0 USD
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
212000 USD
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
0 USD
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
2500000 USD
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-395000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2172000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1215000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1784000 USD
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-371000 USD
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-283000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2921000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2146000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
118000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47895000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37348000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1250000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
342000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1250000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-342000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
30000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
112625000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
40151000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
605000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
259000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
40726000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
112884000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8419000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
75194000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
192646000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
139198000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
184227000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
214392000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
184166000 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
214331000 USD
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
61000 USD
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
61000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
184227000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
214392000 USD
us-gaap Interest Paid Net
InterestPaidNet
617000 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
344000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
320000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58600000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48300000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-213300000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
184200000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of expenses in the condensed financial statements and accompanying notes. Significant items subject to such estimates and assumptions include stock-based compensation, net embedded derivative liability bifurcated from the Credit Agreement and certain research and development accruals. Actual results could differ from these estimates, and such differences could be material to the Company’s financial position and results of operations.</span></div>
CY2021Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
7000000 USD
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
3500000 USD
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3161000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1244000 USD
CY2021Q3 oyst Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1013000 USD
CY2020Q4 oyst Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
3541000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11174000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8285000 USD
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
oyst Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
1 shares
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7088888 shares
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5607032 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3485711 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.74
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
36506000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1479153 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.59
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
171610 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.53
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2272000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
120466 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
19.42
oyst Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue
342000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4672788 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.64
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
17535000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
2058694 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2058694 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7150
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
14885000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4672788 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
12640
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y1M6D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
17535000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.88
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
28800000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
61215 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
23.83
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P1Y4M24D
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
1152000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
154431 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.26
oyst Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGrantsInPeriod
2820000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
32153 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
27.15
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
648000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
4898 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
18.77
oyst Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod
87000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
178595 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
18.56
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y6M
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
2116000 USD
CY2021Q3 oyst Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested And Expected To Vest
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAndExpectedToVest
178595 shares
CY2021Q3 oyst Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue
18.56
oyst Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
P2Y6M
CY2021Q3 oyst Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested And Expected To Vest
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest
2116000 USD
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25984412 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25984412 shares
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3115000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1990000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8843000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4779000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-17670000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-16305000 USD
us-gaap Net Income Loss
NetIncomeLoss
-58595000 USD
us-gaap Net Income Loss
NetIncomeLoss
-48288000 USD
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26037975 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26037975 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25797282 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25797282 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23544035 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23544035 shares
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.05
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4881553 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3269760 shares
CY2021Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
700000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1600000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
400000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
300000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
629000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
644000 USD
CY2021Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
22000 USD
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
34000 USD
CY2021Q3 oyst Lease Right Of Use Asset
LeaseRightOfUseAsset
651000 USD
CY2020Q4 oyst Lease Right Of Use Asset
LeaseRightOfUseAsset
678000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
464000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
400000 USD
CY2021Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
17000 USD
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
18000 USD
CY2021Q3 oyst Lease Liability Current
LeaseLiabilityCurrent
481000 USD
CY2020Q4 oyst Lease Liability Current
LeaseLiabilityCurrent
418000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
172000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
250000 USD
CY2021Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
7000 USD
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
19000 USD
CY2021Q3 oyst Lease Liability Noncurrent
LeaseLiabilityNoncurrent
179000 USD
CY2020Q4 oyst Lease Liability Noncurrent
LeaseLiabilityNoncurrent
269000 USD
CY2021Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
5000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
138000 USD
CY2021Q3 oyst Lease Liability Payments Remainder Of Fiscal Year
LeaseLiabilityPaymentsRemainderOfFiscalYear
143000 USD
CY2021Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
16000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
376000 USD
CY2021Q3 oyst Lease Liability Payments Due Next Twelve Months
LeaseLiabilityPaymentsDueNextTwelveMonths
392000 USD
CY2021Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
4000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
126000 USD
CY2021Q3 oyst Lease Liability Payments Due Year Two
LeaseLiabilityPaymentsDueYearTwo
130000 USD
CY2021Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
0 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
21000 USD
CY2021Q3 oyst Lease Liability Payments Due Year Three
LeaseLiabilityPaymentsDueYearThree
21000 USD
CY2021Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
25000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
661000 USD
CY2021Q3 oyst Lease Liability Payment Due
LeaseLiabilityPaymentDue
686000 USD
CY2021Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
1000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
25000 USD
CY2021Q3 oyst Lease Liability Undiscounted Excess Amount
LeaseLiabilityUndiscountedExcessAmount
26000 USD
CY2021Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
24000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
636000 USD
CY2021Q3 oyst Lease Liability
LeaseLiability
660000 USD
CY2021Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
17000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
464000 USD
CY2021Q3 oyst Lease Liability Current
LeaseLiabilityCurrent
481000 USD
CY2021Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
7000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
172000 USD
CY2021Q3 oyst Lease Liability Noncurrent
LeaseLiabilityNoncurrent
179000 USD
CY2021Q3 oyst Line Of Credit Facility Number Of Tranches
LineOfCreditFacilityNumberOfTranches
3 shares
CY2021Q3 oyst Debt Instrument Prepayment Premium Percentage Period Two
DebtInstrumentPrepaymentPremiumPercentagePeriodTwo
0.08
CY2021Q3 oyst Debt Instrument Prepayment Premium Percentage Period Three
DebtInstrumentPrepaymentPremiumPercentagePeriodThree
0.06
CY2021Q3 oyst Debt Instrument Prepayment Premium Percentage Period Four
DebtInstrumentPrepaymentPremiumPercentagePeriodFour
0.04
oyst Accumulated Amortization Commitment Fee Costs
AccumulatedAmortizationCommitmentFeeCosts
-271000 USD
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
45000000 USD
CY2021Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
2868000 USD
CY2021Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
-450000 USD
CY2021Q3 us-gaap Accumulated Amortization Deferred Finance Costs
AccumulatedAmortizationDeferredFinanceCosts
237000 USD
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
41919000 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
1100000 USD
us-gaap Interest Expense
InterestExpense
1100000 USD
CY2021Q3 oyst Amortization Of Commitment Fees Debt Issuance And Discount Costs
AmortizationOfCommitmentFeesDebtIssuanceAndDiscountCosts
500000 USD
oyst Amortization Of Commitment Fees Debt Issuance And Discount Costs
AmortizationOfCommitmentFeesDebtIssuanceAndDiscountCosts
500000 USD
CY2021Q3 oyst Supply Commitment Initial Term
SupplyCommitmentInitialTerm
P3Y
CY2021Q3 oyst Supply Commitment Minimum Capacity Reservation Fee
SupplyCommitmentMinimumCapacityReservationFee
2500000 USD
CY2021Q3 oyst Supply Commitment Minimum Capacity Reservation Term Of Annual Payments
SupplyCommitmentMinimumCapacityReservationTermOfAnnualPayments
P3Y

Files In Submission

Name View Source Status
0001720725-21-000095-index-headers.html Edgar Link pending
0001720725-21-000095-index.html Edgar Link pending
0001720725-21-000095.txt Edgar Link pending
0001720725-21-000095-xbrl.zip Edgar Link pending
exhibit101-creditagreement.htm Edgar Link pending
exhibit102-jixinglicensing.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
oyst-20210930.htm Edgar Link pending
oyst-20210930.xsd Edgar Link pending
oyst-20210930_cal.xml Edgar Link unprocessable
oyst-20210930_def.xml Edgar Link unprocessable
oyst-20210930_htm.xml Edgar Link completed
oyst-20210930_lab.xml Edgar Link unprocessable
oyst-20210930_pre.xml Edgar Link unprocessable
oyst-q3x21ex311.htm Edgar Link pending
oyst-q3x21ex312.htm Edgar Link pending
oyst-q3x21ex321.htm Edgar Link pending
oyst-q3x21ex322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending